PUMA BIOTECHNOLOGY, INC.
PBYICIK 0001401667 · Pharmaceutical Preparations · Nasdaq
- INNOVATIVE ACQUISITIONS CORP (until 2011-10-04)
Revenue (TTM)
$197.73M
−0.9% YoY
Q1 May 2026
Net Income (TTM)
$13.92M
+2.8% YoY
Q1 May 2026
EPS Diluted (TTM)
$0.28
−1.6% YoY
Q1 May 2026
Gross Margin
77.0%
Q1 May 2026
Operating Margin
8.3%
Q1 May 2026
Net Margin
7.0%
Q1 May 2026
Free Cash Flow (TTM)
$32.82M
Q1 May 2026
Cash
$36.19M
Q1 May 2026
Total Debt
$11.28M
Q1 May 2026
Shares Outstanding
50.9M sh
Q1 May 2026